Tailored Pig Models for Preclinical Efficacy and Safety Testing of Targeted Therapies by Klymiuk, Nikolai et al.
Review Article
Tailored Pig Models for Preclinical Efficacy
and Safety Testing of Targeted Therapies
Nikolai Klymiuk1, Frank Seeliger2, Mohammad Bohlooly-Y3,
Andreas Blutke4, Daniel G. Rudmann2, and Eckhard Wolf1
Abstract
Despite enormous advances in translational biomedical research, there remains a growing demand for improved animal models
of human disease. This is particularly true for diseases where rodent models do not reflect the human disease phenotype.
Compared to rodents, pig anatomy and physiology are more similar to humans in cardiovascular, immune, respiratory, skeletal
muscle, and metabolic systems. Importantly, efficient and precise techniques for genetic engineering of pigs are now available,
facilitating the creation of tailored large animal models that mimic human disease mechanisms at the molecular level. In this
article, the benefits of genetically engineered pigs for basic and translational research are exemplified by a novel pig model of
Duchenne muscular dystrophy and by porcine models of cystic fibrosis. Particular emphasis is given to potential advantages of
using these models for efficacy and safety testing of targeted therapies, such as exon skipping and gene editing, for example, using
the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated system. In general, genetically tai-
lored pig models have the potential to bridge the gap between proof-of-concept studies in rodents and clinical trials in patients,
thus supporting translational medicine.
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Genetically Engineered Pig Models of Human
Monogenic Diseases
Rare monogenic diseases are an attractive market for the phar-
maceutical industry, since they provide—once the underlying
mutation is identified—validated targets for drug development
(Brinkman et al. 2006) or genetic treatment approaches
(O’Connor and Crystal 2006). Development of drugs for these
orphan diseases frequently has higher success rates and shorter
times to approval and may—in spite of much smaller target
patient populations—generate potential lifetime revenues com-
parable to nonorphan drugs (Fagnan et al. 2014). Currently the
molecular etiology for more than half of the estimated 7,000
rare monogenic human diseases is known, and marked accel-
eration of disease gene discovery is expected from the dramatic
improvements in DNA-sequencing technologies and associated
analyses (Boycott et al. 2013). Model organisms are required to
dissect the biological consequences of a particular mutation
and to provide proof of concept for therapeutic intervention.
The mouse is the most widely used model organism in mamma-
lian genetics, and powerful platforms/networks for large-scale
systematic mutagenesis and standardized phenotyping have
been established (Bradley et al. 2012; Infrafrontier Consortium
2015). However, mutant mouse models do not always reflect
the phenotypes of the corresponding human genetic diseases.
Moreover, translation of findings in mouse models into clinical
studies and applications may be difficult. Thus, large animal
models mimicking human anatomy and physiology more
closely are additionally needed. In this respect, the pig as a
monogastric omnivore is an attractive model organism (Aigner
et al. 2010). A detailed discussion of advantages of miniature
swine for use as relevant translational animal model is provided
by Tellez and Shanmuganayagam (in press).
Over the last three decades, a broad spectrum of techniques
for genetic engineering of pigs has facilitated the generation of
large animal models tailored for studying mechanisms of and
testing treatment options for human genetic diseases. A major
breakthrough was the establishment of somatic cell nuclear
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transfer (SCNT) in pigs, which provided for the first time a
technological basis for introducing targeted genetic modifica-
tions in this species (Lai et al. 2002; Dai et al. 2002). The low
rate of gene targeting/homologous recombination (HR) in
somatic cells was overcome by positive/negative selection (Jin
et al. 2003) or gene-trapping strategies (Lai et al. 2002), by
using adeno-associated virus (AAV) targeting vectors (Rogers,
Hao, et al. 2008) or large targeting constructs based on modi-
fied bacterial artificial chromosomes (BACs; Klymiuk, Mund-
henk, et al. 2012; Klymiuk et al. 2013). SCNT also facilitated
the establishment of other sophisticated modifications, such as
inducible transgene expression based on the binary Tet-On sys-
tem (Klymiuk, Bocker, et al. 2012).
The availability of porcine whole genome sequences (Groe-
nen et al. 2012) and the adaptation of efficient gen(om)e editing
technologies, such as zinc finger nucleases (ZFNs; Hauschild et
al. 2011; Whyte et al. 2011), transcription activator-like effec-
tor nucleases (TALENs; Carlson et al. 2012), and RNA-guided
endonucleases derived from the bacterial clustered regularly
interspaced short palindromic repeats (CRISPR)/CRISPR asso-
ciated (Cas) system (Hai et al. 2014), to this species will further
increase the potential to develop tailored pig models of human
monogenic diseases. While ZFNs and TALENs tremendously
improved upon the efficacy and specificity of gene editing, the
complexity of the redesign and construction of the entire pro-
tein for each target limits the use of these technologies (Sander
and Joung 2014). The emergence of CRISPR/Cas9 gene editing
technology provides an easier, faster, and less expensive
genetic engineering approach for generating targeted disease
models in pigs. A novel pig model of Duchenne muscular dys-
trophy (DMD) and pig models of cystic fibrosis (CF) is dis-
cussed in detail subsequently.
A Pig Model of DMD Resembles Biochemical,
Clinical, and Pathological Hallmarks of the
Human Disease
In humans, the severe X-linked disease DMD is caused by loss-
of-function mutations of the DMD gene (*2.5 Mb, 79 exons)
and affects 1 in 3,500 males. Characteristic mutations are losses
of complete exons with hot spots in the regions of exons 3–7 and
exons 45–55. These may lead to shifts in reading frame, out-of-
frame transcripts, and loss of the essential muscle cytoskeletal
protein dystrophin (Hoffman, Brown, and Kunkel 1987). DMD
is characterized by progressive muscle weakness and wasting:
most patients die of respiratory or heart failure between the
second and fourth decade of life (reviewed in Spurney 2011).
Genetic and pharmacological treatment approaches are in
different phases of clinical testing (reviewed in Fairclough,
Wood, and Davies 2013). Existing animal models of DMD pro-
vided insights into disease mechanisms but have limitations
related to the type of DMD mutation and/or the clinical pheno-
type (Nakamura and Takeda 2011).
The original X-linked muscular dystrophy mouse (mdx)
occurred spontaneously in the C57BL/10 strain and has a
nonsense mutation in exon 23 of the Dmd gene. Four further
mdx mice strains have been identified with different mutations.
In addition, an mdx mouse lacking Dmd exon 52 has been gen-
erated by gene targeting (Araki et al. 1997). However, mdx
mice do not develop overt muscle wasting except for the dia-
phragm and have a near-normal life span. The disparity in
pathological consequences of dystrophin loss in DMD patients
and the mdx mouse has been attributed to different patterns of
muscle growth and regeneration (Partridge 2013).
In addition, mutations in the DMD gene have been identified
in several dog breeds, with golden retriever muscular dystrophy
(GRMD) being the most extensively examined (reviewed in
McGreevy et al. 2015). GRMD dogs are more severely affected
than mdx mice, but display a highly variable phenotype, and are
difficult to breed. Further, the DMD mutation of the GRMD
model (point mutation at the intron 6 splice acceptor site, lead-
ing to skipping of exon 7, and a premature stop codon in exon
8) does not reflect the situation in the majority of human DMD
patients with a hot spot for deletions between exons 45 and 55
of the DMD gene. In addition to GRMD, DMD mutations have
been identified in 8 other dog breeds, but most studies are lim-
ited to case reports (reviewed in McGreevy et al. 2015). A
severe feline muscular dystrophy with dystrophin deficiency
is caused by a large deletion in the promoter region of the DMD
gene, but it has not been used as a model for testing therapeutic
approaches (reviewed in Nakamura and Takeda 2011).
Recently generated rat models of DMD have either CRISPR/
Cas-induced deletions between exons 3 and 16 (Nakamura et
al. 2014) or a TALEN-induced 11-bp deletion in exon 23 of the
Dmd gene (Larcher et al. 2014), resulting in dystrophin defi-
ciency. The DMD rats showed muscle weakness and histologi-
cal signs of muscular dystrophy. However, no treatment studies
were reported so far and findings from such studies may be—
due to the small size of rats—difficult to extrapolate to humans.
Very recently rhesus monkeys with mutant DMD alleles were
generated by using CRISPR/Cas for injection into fertilized
oocytes (Y. Chen et al. 2015). Although partial dystrophin
depletion and hypertrophic myopathy were observed, the mon-
keys were mosaic, resulting in genetic and phenotypic variabil-
ity, which limits their value as translational animal models.
To establish a tailored large animal model of DMD, we
deleted DMD exon 52 in male pig cells by gene targeting using
a modified BAC and generated DMD mutant pigs by nuclear
transfer (Klymiuk et al. 2013). Cloned DMD pigs lacked dys-
trophin in skeletal muscles and exhibited increased serum crea-
tine kinase levels, impaired movement and muscle weakness,
and a maximum life expectancy of 14 weeks. Pathological
analysis of DMD pigs demonstrated pale moist skeletal mus-
cles with multifocal areas of pale discoloration. Histological
examination revealed a myopathy with excessive fiber size var-
iation, numerous large rounded hypertrophic fibers, branching
fibers and fibers with central nuclei, as well as scattered clus-
ters of segmentally necrotic fibers, next to hypercontracted
fibers and groups of small regenerating muscle fibers
(Figure 1). These lesions were accompanied by interstitial
fibrosis and mononuclear inflammatory cell infiltration,
Klymiuk et al. 347
mimicking the hallmarks of the human disease. The severity
and extent of these alterations progressed with age (Klymiuk
et al. 2013).
Transcriptome studies of skeletal muscle from young
(2 days old) and older (around 3 months) DMD pigs and
age-matched controls provided new insights into the hierar-
chy of physiological derangements of dystrophic muscle. The
transcriptome changes in 3-month-old DMD pigs were similar
to those of human DMD muscle, reflecting the processes of
degeneration, regeneration, inflammation, fibrosis, and
impaired metabolic activity. In contrast, the transcriptome
profile of muscle samples from 2-day-old DMD pigs showed
similarities with transcriptome changes induced by acute
exercise muscle injury, suggesting mechanical stress on the
muscle cell membranes as an early factor in the pathogenesis
of DMD (Klymiuk et al. 2013).
DMD pigs exhibit the functional and pathological hallmarks
of the human disease but develop them in an accelerated man-
ner. This offers improved opportunities for early and clear-cut
readouts in efficacy studies of new treatments as compared to
the currently available animal models. Since loss of exon 52
is a frequent mutation in human DMD, which can be treated
by exon skipping (reviewed in Fairclough, Wood, and Davies
2013), this pig model has the potential to test and refine this
therapeutic strategy.
A limitation of the published DMD pig model (Klymiuk et
al. 2013) is that it cannot be propagated by breeding, since
cloned male pigs do not survive until the age of sexual matu-
rity. Therefore, we introduced the DMDDexon52 mutation in
female cells and generated female carrier pigs by SCNT. The
first litter from a female carrier mated with a wild-type boar
contained male DMD piglets, female DMDDexon52 carriers as
well as male and female wild-type piglets according to the
expected Mendelian ratio (Figure 2A). Studies are in progress
to characterize the phenotype of DMD pigs generated by breed-
ing at the biochemical, clinical, and pathological level as done
previously (Klymiuk et al. 2013). At the age of 1 week, the
male DMD piglets showed already markedly elevated serum
creatine kinase levels (Figure 2B), indicating degeneration of
muscle fibers. Breeding of female DMDDexon52 carriers will
allow us to produce sufficient numbers of DMD piglets for sys-
tematic testing of targeted therapies as outlined subsequently.
DMDDexon52 Yucatan minipigs have been developed by
Exemplar Genetics, Inc., and a limited characterization is
included in their patent application WO2014117045A2.
Pig Models of CF Provide Important Insights
into Early Disease Mechanisms
CF is the most frequent inherited disease in Caucasians and
affects *70,000 individuals worldwide (Cutting 2015). The
causative gene CFTR encoding the CF transmembrane conduc-
tance regulator, an epithelial anion channel, was identified
decades ago. Almost 2,000 mutations of CFTR have been
reported, with deletion of phenylalanine at position 508
(F508del) being most common (Sosnay et al. 2013). The latter
causes aberrant folding of CFTR and subsequent degradation
of the majority of the synthesized protein. If F508del-CFTR
is trafficked to the cell membrane, it has reduced membrane
residency and aberrant chloride channel function (reviewed
in Cutting 2015). CF is a multisystemic disease affecting the
airways, the gastrointestinal tract including pancreas and hepa-
tobiliary system, and the reproductive tract. Chronic bacterial
infections and persistent inflammatory processes of the lung
are the main cause of morbidity and mortality associated with
CF (reviewed by Elston and Geddes 2007).
While defective transepithelial electrolyte transport plays a
role, there is no comprehensive explanation of the disease
pathogenesis in the affected organs. This is mainly due to the
lack of translational animal models that reflect the human dis-
ease phenotype sufficiently well. Although numerous Cftr
mutant mouse models have been established, they reproduce
the disease processes going on in CF patients only partially
(reviewed by Wilke et al. 2011). This is particularly true for the
pathology of the respiratory tract, which is the most important
cause of the declining patient’s quality of life leading to death.
A CFTR-deficient rat model was reported to exhibit histologi-
cal abnormalities in the ileum and increased intracellular
mucus in the proximal nasal septa, reduced airway surface
Figure 1. Severe muscular dystrophy in Duchenne muscular dystro-
phy (DMD) pigs. Cross sections of the biceps femoris muscle of a wild
type (A) and a DMD pig (B) at 3 months of age. DMD pigs display vari-
able muscle fiber diameters: large, rounded fibers with internalized
central nuclei and necrosis of muscle fibers. Plastic (glycol methacry-
late and methyl methacrylate) sections, 20 objective, H&E stains.
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liquid and periciliary liquid depth, and abnormal submucosal
gland size (Tuggle et al. 2014). However, although the CF rat
recapitulates several aspects of human CF (aberrant chloride
transport, intestinal obstruction, impaired growth, malforma-
tion of the trachea, and anomalous vas deferens), important
hallmarks such as obstructive lung disease, dysfunction of liver
and exocrine pancreas, and diabetes mellitus were not reported
in this model (reviewed in Cutting 2015).
Only recently have nonrodent animal models of CF been
established. CFTR-deficient pig models were generated by
introducing a stop codon in exon 10 (Rogers, Stoltz, et al.
2008) or a STOP box that terminates both transcription and
translation in exon 1 (Klymiuk, Mundhenk, et al. 2012). In a
third CF pig model, the most relevant human CFTR mutation
F508del in exon 10 was reproduced (Ostedgaard et al. 2011).
In spite of the different CFTR mutations, the models revealed
almost identical phenotypes. One of the major hallmarks is the
(almost) 100% penetrance of meconium ileus (MI), a mechan-
ical obstruction of the gut that occurs in human patients as well,
albeit at a frequency of only 10–20% (Kelly and Buxbaum
2015). Neither ileostomy, that is, surgical removal of meco-
nium, nor intensive enema, which resembles the standard treat-
ment of MI in human patients, was sufficient to resolve this
obstruction in CF pigs, which usually die at the age of several
weeks. Stoltz et al. (2013) generated a ‘‘gut-corrected’’ CF pig
expressing in the gut a CFTR transgene under the control of the
rat fatty acid binding protein 2 promoter. This transgenic rescue
can extend life to up to 12 months; however, in-depth evalua-
tion of CF pigs has been performed only in the neonatal state
and in a limited number of ileostomized pigs. Despite these
limitations, the CF pig model has contributed tremendously
to the understanding of CF pathogenesis. In particular, the
availability of neonatal material that can be seen as a ‘‘native’’
tissue revealed novel insights into the very early steps of CF
development.
Progressive obstruction of the respiratory tract is the most
important cause of morbidity in CF patients. While histological
examination of newborn CF pigs revealed apparently normal
lung tissue (Rogers, Stoltz, et al. 2008), the trachea had a trian-
gular rather than a circular shape and the cartilage appeared
thicker and more discontinuous than in wild-type samples
(Meyerholz et al. 2010; Klymiuk, Mundhenk, et al. 2012). This
was confirmed in human CF infants (Meyerholz et al. 2010;
Diwakar et al. 2015). In accordance to the findings in CF
patients, sinus disease developed spontaneously in older CF
pigs, whereas at birth sinuses were hypoplastic but did not
show evidence of infection or inflammation (Chang et al.
2012). Although the lungs of the newborn CF piglets did not
show signs of infection, defective bacterial eradication was
observed (Stoltz et al. 2010) and attributed to the decreased
pH on airway epithelia, which has been postulated to impair
bacterial killing (Pezzulo et al. 2012). Furthermore, mucus
Figure 2. Generation of Duchenne muscular dystrophy (DMD) pigs by breeding. (A) Heterozygous DMD mutant sow with her first litter pro-
duced by mating to a wild-type boar. The heterozygous DMD mutant sow was generated by somatic cell nuclear transfer from a female cell clone
in which exon 52 of one DMD allele was deleted by bacterial artificial chromosome targeting as described by Klymiuk et al. (2013), while the other
DMD allele was intact. Male DMD piglets (marked by an arrow), female carriers (marked by an asterisk), and wild-type pigs were obtained accord-
ing to the expected Mendelian ratio. (B) Serum creatine kinase activities are elevated already in 8-day-old DMD pigs, indicating damage and decay
of muscle fibers. Note that the heavily outlined circle in the wild-type group is from 2 animals (Nikolai Klymiuk, Barbara Keßler and Eckhard Wolf,
unpublished).
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detachment from submucosal glands of the airways has been
shown to be impaired (Hoegger et al. 2014).
Analyses of epithelial tissue and cultivated cells from CF
pigs revealed that the lack of CFTR caused reduced transcellu-
lar transport of Cl and HCO3
, but no alteration of Naþ trans-
port or liquid absorption was reported (J. H. Chen et al. 2010).
This was later confirmed in primary epithelial cells from
human CF patients (Itani et al. 2011). This was a major para-
digm shift driven by interrogation of the pig model, as the
thickening of mucus in CF airways has been postulated to occur
from a disturbance of osmolaric balance, whereas the pig
model data suggested a Naþ-independent mechanism. Conse-
quently, these data challenged the relevance of mouse models
overexpressing the epithelial Naþ channel, the only mouse
model showing mucus thickening in the airways, for CF
research (Collawn et al. 2012).
In conclusion, the established CF pig lines provide excellent
models to study early mechanisms of lung disease and to eval-
uate therapeutic strategies in newborn animals.
A ferret model of CF was generated by Sun et al. (2010).
The phenotypic changes in this model correspond to those of
the pig models and have been reviewed recently (Yan et al.
2015).
The Potential Role of DMD and CF Pig
Models for Evaluating Targeted Therapies
The recent developments of large animal models are benefit-
ting treatment strategies for both DMD and CF.
Genetic approaches to cure DMD include replacing the
defective DMD gene, readthrough of translation stop codons,
exon skipping to restore the reading frame, and increased
expression of the utrophin (UTRN) gene, which may compen-
sate the loss of dystrophin (reviewed in Fairclough, Wood, and
Davies 2013).
Challenges for gene therapy of DMD include the large size
of the DMD mRNA (14 kb) and the need to target all muscles.
DMD mini- and micro-genes have been developed to overcome
the size problem of full-length DMD complementary DNA
(reviewed in Davies 2013). The most commonly used viral vec-
tors to transduce muscle cells are based on AAV; however,
DMD gene delivery by using this vector has resulted in immune
responses against mini-dystrophin (reviewed in Davies 2013).
Readthrough strategies for nonsense mutations use small
molecule drugs such as aminoglycosides or ataluren (PTC124)
that introduce a conformational change in the mRNA and allow
the ribosome to insert an amino acid at a premature stop codon
site during translation. This approach has been estimated to be
applicable in *13% of patients with Duchenne/Becker muscu-
lar dystrophy (Finkel 2010). Clinical studies of ataluren demon-
strated dystrophin expression (Finkel et al. 2013) and a positive
effect on the outcome of a 6-min walk distance (6MWD) test
(Bushby et al. 2014). However, this study observed an unexpect-
edly large standard deviation of the 6MWD scores over 48
weeks, and the levels of dystrophin in muscle biopsies were dif-
ficult to interpret due to the poor sample quality.
Exon skipping is another strategy that could work for more
than 80% of all DMD mutations, including most out-of-frame
deletions (reviewed in Fairclough, Wood, and Davies 2013).
The aim of this strategy is to restore an intact reading frame
of the transcript. Skipping of specific exons can be induced
by intramuscular or systemic treatment with RNaseH-indepen-
dent antisense oligonucleotides (AONs), which hybridize to
complementary sequences in or adjacent to the target exon.
20-O-methyl-phosphorothioate AONs and morpholino phos-
phorodiamidate oligonucleotides have been tested in preclini-
cal studies and clinical trials (reviewed in Fairclough, Wood,
and Davies 2013) but have failed to show clear clinical benefit.
A new class of AONs made of tricyclo-DNA (tcDNA) rescued
dystrophin expression in skeletal muscles and heart and to a
lower level in the central nervous system of mdx mice (Goyen-
valle et al. 2015). Improvement of several clinical parameters
was reported in tcDNA AON-treated mdx mice and also in dou-
ble mutant mice which lack both dystrophin and UTRN and
show a more severe phenotype than the mdx mice.
In spite of these promising results in dystrophic mouse
models, it would be beneficial to test the efficacy of this new
exon skipping strategy in a clinically severe large animal
model before moving forward to clinical trials because a num-
ber of questions cannot be easily addressed in DMD patients.
These include (1) the best timing to initiate AON therapy
related to disease progression; (2) the amount of dystrophin
required for near normal muscle function; (3) the optimal
study duration, readouts, and outcome measures; (4) the best
effective systemic administration route; and (5) the optimal
dosage for a long-term therapy. Since our DMD exon 52-defi-
cient pig model is amenable to correction by skipping of exon
51 or 53 and can now be provided by breeding in sufficient
numbers for systematic studies, it appears to be ideally suited
for testing this new promising approach of exon skipping. In
addition, the DMD pig is useful to clarify efficacy and safety
aspects of AAV-DMD mini-gene therapy, including potential
immunological complications, and of readthrough treatment
strategies or cellular therapies. In comparison with the exist-
ing canine DMD models, studies in DMD pigs may be ethi-
cally more acceptable.
The existing CF pig models are useful for optimizing gene
therapy approaches, delivery, and safety. Gene therapy of CF
using viral vectors (adenovirus [ADV], AAV2, and lentivirus
[LV]) and nonviral vectors (reviewed in Griesenbach and Alton
2009; Prickett and Jain 2013) has not yet led to a clinically
applicable therapy but have uncovered a number of problems
limiting the efficacy of gene therapy for CF patients. These dif-
ficulties include challenges with the local delivery of gene
therapy vectors into epithelial cells through a thickened mucus
layer and immune reactions against the viral vectors. A recent
clinical trial of repeated nebulization of nonviral CFTR gene
therapy in CF patients revealed a significant, albeit modest,
treatment effect with a stabilization of lung function (Alton
et al. 2015). Large CF animal models with an airway and lung
structure similar to CF patients will help improve vector design
and delivery strategies. For example, Cao et al. (2013)
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demonstrated efficient transfer of LacZ reporter genes and
human CFTR expression cassettes into airway epithelia and
submucosal glands of normal pigs after intratracheal applica-
tion of aerosolized helper-dependent ADV. In addition, intra-
tracheal delivery of transfected airway epithelial cells has
been suggested as treatment of CF, and proof of principle for
efficient delivery of such cells has been shown in mice and
wild-type pigs (Gui et al. 2015). It will be interesting to test
these strategies in CF pigs, where gene or cell delivery may
be more challenging because of the preexisting mucus and
inflammation. CF pigs are also an interesting model for testing
viral CFTR gene delivery via the celiac artery into the pancreas,
a technique that has been recently established in wild-type pig-
lets (Griffin et al. 2014).
The F508del-CFTR pig model can be used for evaluating
combinations of CFTR correctors and potentiators. CFTR cor-
rectors, such as lumacaftor, reverse the folding defect of
F508del-CFTR and increase its amount. CFTR potentiators,
such as ivacaftor, increase the activity of the folding-corrected
F508del-CFTR (reviewed in Cutting 2015).
Correction of Genetic Defects Using the
CRISPR/Cas System
A recent major advancement is the use of genome editing tools
like the CRISPR/Cas system. These systems are transforming
the versatility, flexibility, and efficiency in the development
of translatable animal models, including pigs (reviewed in
Redel and Prather in press, this issue of Toxicologic Pathol-
ogy), and offer great potential for treating diseases due to
genetic defects. The concept of genome editing is based on the
introduction by a programmable nuclease of a site-specific
DNA double-strand break (DSB), which undergoes repair by
different cellular repair mechanisms. One is nonhomologous
end joining (NHEJ), which is induced by binding of KU hetero-
dimers and associated repair proteins to the ends of DSB.
The KU heterodimer is composed of the KU70 and KU80 sub-
units. Once the KU heterodimer is bound to the DSB ends, it
recruits other NHEJ factors, including DNA-dependent protein
kinase, catalytic subunit, X-ray cross-complementing protein 4
(XRCC4), DNA ligase IV, XRCC4-like factor, and aprataxin-
and PNK-like factor, to process the DSB ends and facilitate
their ligation (reviewed in Davis and Chen 2013). NHEJ is
error prone, often leading to insertions or deletions, frameshift
mutations, and gene knockouts. Alternatively, repair by HR
can be directed by binding of RAD51 to DSB ends, followed
by recruitment of accessory factors that direct HR with the
matching sister chromatid or with homology regions of an
exogenous repair template (Figure 3). The latter allows the
introduction of precise genetic modifications or the correction
of specific mutations (reviewed in Hsu, Lander, and Zhang
2014). The most widely used site-directed nucleases are ZFNs,
TALENs, and the bacterial CRISPR/Cas system. The pros and
cons of these systems have been subject to several recent
reviews (Hsu, Lander, and Zhang 2014; Kim and Kim 2014).
The CRISPR/Cas9 system was discovered when investigat-
ing the natural innate immune system of bacteria against virus
infections (reviewed in Sander and Joung 2014). The break-
through was in the recognition that the CRISPR/Cas9 system
from Streptococcus pyogenes could be adapted for targeting
and editing the genome precisely in any in vivo or ex vivo
model (Deltcheva et al. 2011). The CRISPR/Cas system has
attracted major attention and is now widely used since the site
specificity of the Cas9 nuclease is provided by a single-guide
RNA (sgRNA), which is easier and faster to engineer than
ZFNs or TALENs where FokI endonuclease needs to be fused
to specific DNA-binding proteins to generate programmable
site-specific nucleases.
Several modifications of the CRISPR/Cas system have been
developed, such as a new generation of Cas9, which increases
the direction of DNA repair to HR and at the same time reduces
the risk of off-target effects. A mutated variant of the enzyme,
called nickase, is only capable of cutting 1 single DNA strand
at a time (nick). By inducing 2 neighboring single-strand
breaks, a DSB-like cut can be achieved and direct the conclud-
ing repair event to the HR pathway (reviewed by Sander and
Joung 2014). In addition, the sgRNA-directed catalytically
inactive or ‘‘dead’’ Cas9 can be fused to activation domains
to mediate upregulation of specific endogenous genes
(reviewed by Sander and Joung 2014). A potential application
in DMD would be the targeted upregulation of UTRN to com-
pensate for the loss of dystrophin.
Recently the CRISPR/Cas9 system has been used to correct
the Dmd mutation in exon 23 of the mdx mouse (Long et al.
2014). The authors injected an sgRNA targeting Dmd exon
23, Cas9 mRNA, and a single-stranded oligodeoxynucleotide
as template for HR-mediated gene repair into zygotes from mdx
mice and transferred the embryos to pseudopregnant recipients.
The resulting offspring turned out to be genetic mosaics with
2–100% Dmd alleles corrected by HR. In addition, restoration
of an intact reading frame by NHEJ was observed. Strikingly,
correction of less than 20% of the mutant Dmd alleles was suf-
ficient to restore dystrophin expression in a majority of myofi-
bers with a level comparable to that of wild-type mice. This
was explained by the multinucleated structure of myofibers,
where correction of the Dmd gene in a subset of nuclei may
be sufficient to restore dystrophin in the entire myofiber.
Fusion of corrected satellite cells with dystrophic fibers might
also contribute to the restoration of dystrophin expression and
to the regeneration of dystrophic muscle (Long et al. 2014).
Another study used CRISPR/Cas9 with single or multi-
plexed sgRNAs to restore the DMD reading frame by targeting
the mutational hot spot at exons 45–55 and introducing shifts
within exons or deleting one or more exons in cultured myo-
blasts from DMD patients. Dystrophin expression could be
restored in vitro and remained stable after transplantation of the
cells into tibialis anterior muscles of immunodeficient mice
(Ousterout et al. 2015).
The promising results of these studies clearly open the per-
spective for CRISPR/Cas9-mediated correction of DMD muta-
tions in postnatal muscle cells of Duchenne patients, if
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appropriate delivery systems for the components of the
CRISPR/Cas9 system can be developed. AAV, in particular
AAV9 serotype providing robust expression in skeletal muscle,
heart, and brain, as well as injection of naked plasmid DNA,
chemically modified mRNA, and nanoparticles containing
nucleic acid have been discussed as potential solutions to meet
this challenge (Long et al. 2014).
For CF, proof of concept for a functional repair of mutant
CFTR by the CRISPR/Cas9 system was first demonstrated in
intestinal stem cell organoids of CF patients (Schwank et al.
2013), and efficient vectors based on helper-dependent ADV
(Cao et al. 2013) are available for testing this strategy in vivo.
Due to the small size of rodents, concepts proven in these mod-
els may be difficult to scale up to a level where clinical feasi-
bility can be demonstrated. In this respect, large animal models
such as the DMD pig (Klymiuk et al. 2013) and CFTR mutant
pigs will be critically important to evaluate efficacy and safety
issues of the CRISPR/Cas9 system in vivo, especially for long-
term use.
Risk Assessment for Genome Editing
Technologies
The therapeutic use of genome editing technologies in vivo or
ex vivo requires very specific safety considerations with regard
to the used technology, the choice of the gene delivery system,
and the most relevant preclinical species. For all areas, the tox-
icological pathologist can contribute to a successful design and
development of a gene editing strategy and therapy.
Briefly, for all genome editing platforms, the specificity of
targeting a gene is of major importance and off-target effects,
that is, mutagenesis of nontarget sequences, must be reduced
to a minimum. Compared to other gene therapeutic approaches,
the introduction of the CRISPR/Cas9 system promises a huge
step ahead toward a safer and more specific gene editing tech-
nology (Sander and Joung 2014). Recent progress in the design
of the sgRNA, the engineering of the Cas9 enzyme, and a better
understanding of the correlation between the concentration of
the Cas9 protein and its on- or off-target activity leads further
toward these goals (Corrigan-Curay et al. 2015). Off-target
sites can be predicted using sophisticated bioinformatic tools
such as PROGNOS (http://baolab.bme.gatech.edu/Research/
BioinformaticTools/prognos.html) and off-target DSB can be
identified in a genome-wide unbiased manner by sequencing-
based methods, such as GUIDE-seq (Tsai et al. 2015). Despite
these technical advances, evaluating off-target activity of any
of these gene editing systems is a challenge in animal models.
The differences between the animal and human genomes will
result in off-target activity that likely will not accurately pre-
dict effects in man. Human in vitro systems using patient or
volunteer-derived cells (e.g., induced pluripotent stem cells)
are likely necessary in addition to animal models for gaining
a full understanding of the potential for off-target gene editing
effects preclinically.
The choice of the right delivery system for gene editing
tools depends on the capacity, efficacy of delivery, targeting
of specific tissues and cell types, and the possibility of spe-
cies-specific adverse reactions. The 2 major classes of delivery
systems, which have been entered into clinic trials, are based on
viral or nonviral vector platforms (reviewed by Sheridan 2011).
Common viral delivery systems are genome integrated retro-
viruses (RV) and LV as well as genome nonintegrated ADV,
AAV, or modified herpes simplex virus (HSV; Hareendran et
al. 2013; Thomas, Ehrhardt, and Kay 2003), and for most,
except the HSV, the use of CRISPR/Cas9 has been successfully
demonstrated (Schmidt and Grimm 2015). All systems need to
overcome the host immune response that occurs at different
levels. In principle, all viral vectors have the potential to be
recognized as an infection and therefore stimulate the immuno-
logical defense system by recognition of viral gene products,
capsid proteins, foreign components of the gene editing tool
package, like the Cas9, or foreign transgene products (Thomas,
Ehrhardt, and Kay 2003).
Figure 3. Principles of genome editing. Designer nucleases comprise
a DNA-cutting domain as well as a unit that directs the DNA-cutting
domain to a desired site in the genome. Three types of nucleases are
regularly used: zinc finger nucleases and transcription activator-like
effector nucleases are synthetic enzymes that both use FokI as a
DNA-cutting domain, whereas the DNA-binding unit is either consti-
tuted of serially assembled zinc finger motifs or of DNA-binding
domains of transcription activator-like effectors. As FokI induces only
single-strand breaks, a pair of inverted nucleases is necessary to
induce a double-strand break (DSB). In contrast, CRISPR/Cas9 and
other RNA-guided endonucleases bind to their targets via a specific
RNA element that is linked to a protein that directly introduces a DSB
via its RuvC and HNH domains. Genomic modifications are intro-
duced during DSB repair by nonhomologous end joining (NHEJ),
micro-homologous end joining (MHEJ), or homologous recombina-
tion (HR). NHEJ fixes the DSB via blunt end ligation, whereas MHEJ
uses micro-homologies of a few base pairs in size located around the
DSB. In both processes, the exact kind of modification cannot be pre-
dicted but often insertions or deletions result in the knockout of the
targeted gene. For introducing a defined mutation, HR with exogen-
ous DNA that carries the desired modification as well as regions of
homology to the target site has to occur. Exogenous DNA has to
be cotransfected with the DSB-introducing nuclease and can be used
for the generation of a knockout, a knockin, or the repair of a gene.
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The toxicological pathologist should be prepared to face a
spectrum of morphological changes, which can range from
local, tissue-limited, inflammatory reactions to massive sys-
temic, cytokine-driven inflammation, eventually resulting in
disseminated intravascular coagulation, multiorgan failure, and
death. Furthermore, for ADV, a dose relationship has been
described between virus dose and cell toxicity and is character-
ized by a threshold-like immune response (Thomas, Ehrhardt,
and Kay 2003).
LV and AAV vectors have become more attractive since
they seem to avoid initial immune responses, but still the
transgene product can elicit such an effect (Hareendran et
al. 2013). To limit the drawbacks of other virus vehicle
systems, engineered AAV vectors like recombinant AAV
serotype variants have become a focus of intensive research
due to their nonpathogenic character, lower immunogenicity
profile, lower oncogenic risk for insertional mutagenesis, and
specific tissue tropism compared to other vectors (Hareendran
et al. 2013; Masat, Pavani, and Mingozzi 2013). In preclinical
studies, AAV vectors demonstrated favorable characteristics,
targeting a broad variety of tissues and providing a stable
transgene expression and a low immunogenicity (Asokan,
Schaffer, and Samulski 2012). The integration of virus gen-
ome, which is the case for LV and RV transduction, may
result in an increased risk for genotoxicity and insertional
mutagenesis by stimulation of oncogenes or inhibition of
tumor suppressor genes with an increased risk for tumorigen-
esis (Schmidt and Grimm 2015).
A significant spectrum of nonviral gene delivery methods
including naked plasmids, polymers, liposomes, peptides, and
inorganic particles have been explored both preclinically and
clinically (reviewed by Yin et al. 2014). Lipid nanoparticles
(LNPs) have been investigated for delivery of different DNA
and RNA species (microRNA and small interfering RNA) as
well as plasmid vectors. LNPs have a lower rate of efficacy
compared to viral vectors and an increased risk of stimulation
of the immune system and inducing inflammation, limiting the
spectrum of recommended tissue for genome targeting
approaches (Yin et al. 2014). As discussed subsequently, for
evaluating the safety of these delivery methods, the toxicologic
pathologist must consider the spectrum of safety relevant end
points appropriate for the gene delivery method and preclinical
safety plans have to be adapted.
In general, the therapeutic use of genome editing technolo-
gies in vivo or ex vivo requires very specific considerations with
regard to preclinical risk assessment. Regulatory guidance is
available (U.S. Department of Health and Human Services,
Food and Drug Administration 2013), but this field is develop-
ing rapidly and close communication with regulators will
enable a fit-for-purpose perspective and approach, both critical
for effective and efficient clinical development. The industry
guidance was developed by the Center for Biologics Evaluation
and Research and supports preclinical design for investiga-
tional cellular therapies, gene therapies, therapeutic vaccines,
xenotransplantation, and biologic-device combination prod-
ucts. For the purpose of this summary, we will focus on
discussions most germane to the toxicologic pathologist as a
principal investigator.
One of the most important considerations for the preclinical
development program is the selection of the animal model for
safety assessment. When evaluating safety it is critical that the
animal demonstrates a biological response to the test product
and that there is sufficient comparability of anatomy and phy-
siology to humans. Compared to the rodent, pig anatomy and
physiology are more similar to humans in regard to the cardio-
vascular, immune, respiratory, skeletal muscle, and metabolic
systems. The same is true for the organization and sequence
homology of the genome. Gene editing methodologies allow
the design of pig models that may reflect the clinical disease
better than rodents, as exemplified by the DMD and CF pig
models discussed in this review. The pig also affords flexibility
in the development of delivery systems/procedures that closely
imitate the approach for the clinic. Therefore, innovative mod-
els based on genetically engineered pigs are an area of rapid
growth in the safety assessment of gene therapy products. The
toxicologic pathologist should be a key partner for summariz-
ing the rationale of a specific animal model in the preclinical
section of the investigative new drug (IND) application or sim-
ilar regulatory document.
As implied earlier in this review, the use of animal models
that approximate the human disease may better define the
risk–benefit ratio associated with a gene therapy product. Chal-
lenges with these disease models include technical limitations
and inherent variability, further complicated by the limited his-
torical safety data and the fact that these models are often not
performed in good laboratory practices (GLP)-compliant facil-
ities. The regulators afford some flexibility for GLP in these
situations; therefore, the lack of a GLP-compliant facility is not
an insurmountable hurdle. While historical safety data may not
be available for the disease model, the use of pretest data for
clinical pathology parameters and the information available for
the founder animals can overcome some of this risk. The tox-
icologic pathologist should take a leadership role in guiding the
team on the inherent limitations of any model and put forward a
tiered, balanced recommendation and risk mitigation plan for
the project.
Once the animal model(s) is/are selected, the design of the
studies must develop a data set that allows for the safe conduct
of clinical proof-of-concept studies. Ideally from the animal
model(s), one has a rigorous data set that highlights the pro-
jected pharmacologically effective dose range and optimal dos-
ing schedule as well as a thorough understanding of the tissue
distribution of the gene therapy product and the potential bio-
logical activities, both wanted and unwanted. Taken together,
these data are used for the IND filing or similar and will inform
the clinical investigator and patient on the projected risks and
benefits of the therapy. Safety end points are included for char-
acterization of the potential toxicities associated with the phar-
macological activity associated with the gene therapy product
and potential effects of the delivery vehicle, transporter system,
or the gene editing tool and its constituents. For the toxicologic
pathologist, the parameters evaluated are very similar to those
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for a program evaluating the safety of a small molecule or bio-
logic and include clinical pathology, organ weights, and gross
and histopathology. Specialized histopathology such as immu-
nohistochemistry and tissue microarrays in addition to molecu-
lar tools like deep sequencing may be a useful adjunct for the
quantification of gene product expression in different tissues
(both target and nontarget). Also because of the inherent risk
for immunologic responses to the transporter system or key
constituents of the gene editing tool, advanced methods for
examination of immunopathologic effects may be warranted.
These could include cytokine analysis, flow cytometry, or other
immunotoxicologic measures of innate and adaptive immunity.
There are a few unique characteristics for the design of a
preclinical safety package for gene therapy products. First, the
normal paradigm of studies progressing from shorter term (2
weeks–1 month) to longer (up to 6 month–1 year) in a rodent
and a nonrodent model may not be appropriate. However, the
understanding of the chronic effects of the gene engineering
product (or delivery system/transporter system/gene editing
tool) may require longer-term studies. In fact, because integrat-
ing viral vectors or stem cells may be key constituents of a gene
therapy product, studies assessing the carcinogenicity potential
often occur earlier in a development program than would be the
case for a small molecule or biologic. Also it is possible that the
species specificity of the gene therapy product would justify a
rationale for only using 1 species (rodent or nonrodent) or alter-
natively a translatable animal disease model for preclinical
safety studies. In any case, close interaction between the toxi-
cologic pathologist and the regulatory agencies is key in the
planning of these studies. Generally, dosing (number and fre-
quency) in animal models mimics the clinical approach. There-
fore, the number of doses for a gene therapy product may be
limited no matter what the observation period is. Notably, the
limited number of doses and the lower milligram per kilogram
requirements for gene therapy products may result in less of a
preclinical pharmaceutical development hurdle for these stud-
ies as compared to preclinical studies for a small molecule or
biologic in larger species like the pig.
Conclusions and Perspectives
Tailored large animal models, especially pigs, have the poten-
tial to bridge the gap between proof-of-concept efficacy and
safety studies in rodent models and clinical trials. Due to major
advancements in technologies for genetic engineering of pigs,
there are models for numerous disease areas, including cancer
(reviewed by Flisikowska, Kind, and Schnieke 2013), meta-
bolic diseases (reviewed by Wolf et al. 2014), and neurodegen-
erative diseases (reviewed by Dolezalova et al. 2014). As a next
step, standardized phenotyping protocols such as those
described by Albl et al. (in press) in this issue of Toxicologic
Pathology will be required to fully exploit the translational
potential of these novel models. These should be developed
in close collaboration between academic partners and experts
from the pharmaceutical industry including toxicologic pathol-
ogists and clinicians to ensure the translational value of the
acquired data. Because the pig is accepted as an appropriate
large animal species for safety assessment, combined safety/
efficacy studies can be designed for the support of clinical
trials. The growing body of knowledge and experience with
genetically engineered large animal models will increase their
acceptance by funding agencies, industry, and regulatory
authorities as an important new element in drug development.
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